Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print November 9, 2005, doi:10.1212/01.wnl.0000188667.66646.1c)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
01.wnl.0000188667.66646.1cv1
66/1/127    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sharma, M. K.
Right arrow Articles by Gutmann, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sharma, M. K.
Right arrow Articles by Gutmann, D. H.
Received July 14, 2005
Accepted September 23, 2005

Matrilin-2 expression distinguishes clinically relevant subsets of pilocytic astrocytoma

M. K. Sharma PhD, M. A. Watson MD, PhD, M. Lyman BS, A. Perry MD, K. D. Aldape MD, F. Deák PhD, and D. H. Gutmann MD, PhD*

From the Departments of Neurology (Drs. Sharma and Gutmann, M. Lyman) and Pathology and Immunology (Drs. Watson and Perry), Washington University School of Medicine, St. Louis, MO, Department of Pathology (Dr. Aldape), University of Texas M.D. Anderson Cancer Center, Houston, and Institute of Biochemistry (Dr. Deák), Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary.


* To whom correspondence should be addressed. E-mail: gutmannd{at}neuro.wustl.edu.

Abstract-- Using whole genome expression microarray technology to discover clinically relevant biomarkers for pilocytic astrocytoma (PA), the authors identified matrilin-2 as a unique mRNA overexpressed in PA. Matrilin-2 protein expression was similarly elevated in the majority of sporadic PA, but in only one neurofibromatosis 1-associated PA with an unusually aggressive clinical phenotype. These results suggest that matrilin-2 may be a specific and clinically useful biomarker for discriminating between indolent and clinically aggressive PA.




This article has been cited by other articles:


Home page
 NeurologyHome page
J. Yu, H. Deshmukh, R. J. Gutmann, R. J. Emnett, F. J. Rodriguez, M. A. Watson, R. Nagarajan, and D. H. Gutmann
Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma
Neurology, November 10, 2009; 73(19): 1526 - 1531.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
A. Tchoghandjian, C. Fernandez, C. Colin, I. El Ayachi, B. Voutsinos-Porche, F. Fina, D. Scavarda, M.-D. Piercecchi-Marti, D. Intagliata, L. Ouafik, et al.
Pilocytic astrocytoma of the optic pathway: a tumour deriving from radial glia cells with a specific gene signature
Brain, June 1, 2009; 132(6): 1523 - 1535.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. S. Houshmandi, E. I. Surace, H. B. Zhang, G. N. Fuller, and D. H. Gutmann
Tumor suppressor in lung cancer-1 (TSLC1) functions as a glioma tumor suppressor
Neurology, November 28, 2006; 67(10): 1863 - 1866.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by AAN Enterprises, Inc.